The Experts below are selected from a list of 143778 Experts worldwide ranked by ideXlab platform
Eric Bellissant - One of the best experts on this subject based on the ideXlab platform.
-
managing Drug Drug Interaction between ombitasvir paritaprevir ritonavir dasabuvir and mycophenolate mofetil
Therapeutic Drug Monitoring, 2017Co-Authors: Florian Lemaitre, Christelle Boglionekerrien, Marieclemence Verdier, Dominique Guyader, Caroline Jezequel, Camille Tron, Eric BellissantAbstract:No Drug-Drug Interaction study has been conducted to date for the combination of ombitasvir, paritaprevir/ritonavir, dasabuvir (3D), and mycophenolic acid (MPA). We here report the case of a hepatitis C virus-infected patient treated with 3D and MPA for vasculitis. In light of the threat of Drug-Drug Interaction, the concentration of MPA was measured before, during, and 15 days after the end of the 3D treatment. Similar values were found at all 3 time points, thus indicating that there is probably no need to adapt MPA dosage to 3D. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
-
managing Drug Drug Interaction between ombitasvir paritaprevir ritonavir dasabuvir and mycophenolate mofetil
Therapeutic Drug Monitoring, 2017Co-Authors: Florian Lemaitre, Christelle Boglionekerrien, Marieclemence Verdier, Dominique Guyader, Caroline Jezequel, Camille Tron, Zeineb Ben Ali, Eric BellissantAbstract:No Drug-Drug Interaction study has been conducted to date for the combination of ombitasvir, paritaprevir/ritonavir, dasabuvir (3D), and mycophenolic acid (MPA). We here report the case of a hepatitis C virus-infected patient treated with 3D and MPA for vasculitis. In light of the threat of Drug-Drug Interaction, the concentration of MPA was measured before, during, and 15 days after the end of the 3D treatment. Similar values were found at all 3 time points, thus indicating that there is probably no need to adapt MPA dosage to 3D.
Florian Lemaitre - One of the best experts on this subject based on the ideXlab platform.
-
managing Drug Drug Interaction between ombitasvir paritaprevir ritonavir dasabuvir and mycophenolate mofetil
Therapeutic Drug Monitoring, 2017Co-Authors: Florian Lemaitre, Christelle Boglionekerrien, Marieclemence Verdier, Dominique Guyader, Caroline Jezequel, Camille Tron, Eric BellissantAbstract:No Drug-Drug Interaction study has been conducted to date for the combination of ombitasvir, paritaprevir/ritonavir, dasabuvir (3D), and mycophenolic acid (MPA). We here report the case of a hepatitis C virus-infected patient treated with 3D and MPA for vasculitis. In light of the threat of Drug-Drug Interaction, the concentration of MPA was measured before, during, and 15 days after the end of the 3D treatment. Similar values were found at all 3 time points, thus indicating that there is probably no need to adapt MPA dosage to 3D. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
-
managing Drug Drug Interaction between ombitasvir paritaprevir ritonavir dasabuvir and mycophenolate mofetil
Therapeutic Drug Monitoring, 2017Co-Authors: Florian Lemaitre, Christelle Boglionekerrien, Marieclemence Verdier, Dominique Guyader, Caroline Jezequel, Camille Tron, Zeineb Ben Ali, Eric BellissantAbstract:No Drug-Drug Interaction study has been conducted to date for the combination of ombitasvir, paritaprevir/ritonavir, dasabuvir (3D), and mycophenolic acid (MPA). We here report the case of a hepatitis C virus-infected patient treated with 3D and MPA for vasculitis. In light of the threat of Drug-Drug Interaction, the concentration of MPA was measured before, during, and 15 days after the end of the 3D treatment. Similar values were found at all 3 time points, thus indicating that there is probably no need to adapt MPA dosage to 3D.
Adriana Carvalhal - One of the best experts on this subject based on the ideXlab platform.
-
a case of a probable Drug Interaction between lurasidone and atazanavir based antiretroviral therapy
Antiviral Therapy, 2016Co-Authors: Mark Naccarato, Elise Hall, Alan Wai, Mario A Ostrowski, Adriana CarvalhalAbstract:The cytochrome P450 isoform that is primarily involved in the metabolism of the antipsychotic lurasidone is CYP3A4. Drugs that inhibit or induce this enzyme would then be expected to increase or decrease serum concentrations of lurasidone, respectively. Atazanavir, an HIV-1 protease inhibitor, has demonstrated to be an inhibitor of CYP3A4 and would be expected to increase the exposure of any Drug metabolized by this enzyme. We report a case of an atazanavir-precipitated Drug-Drug Interaction that led to elevated serum concentrations of lurasidone and associated clinical symptoms of Drug toxicity.
Nuggehally R. Srinivas - One of the best experts on this subject based on the ideXlab platform.
-
differential pharmacokinetic Drug Drug Interaction potential of eletriptan between oral and subcutaneous routes
Xenobiotica, 2019Co-Authors: Harilal Patel, Nirmal D Desai, Prakash Patel, Nirav Modi, Krunal Soni, Nitin Dobaria, Nuggehally R. SrinivasAbstract:1. Pharmacokinetic Drug-Drug Interaction (DDI) data is important from a label claim either in combination Drug usage or in polypharmacy situation.2. Eletriptan undergoes first pass related metaboli...
R R Alloway - One of the best experts on this subject based on the ideXlab platform.
-
evidence of a clinically significant Drug Drug Interaction between cannabidiol and tacrolimus
American Journal of Transplantation, 2019Co-Authors: Abbie D Leino, Chie Emoto, Tsuyoshi Fukuda, Michael Privitera, Alexander A Vinks, R R AllowayAbstract:Cannabidiol (CBD), a major purified nonpsychoactive component of cannabis with anticonvulsant properties, was approved by the U.S. Food and Drug Administration (FDA) in June 2018 as an adjuvant treatment for refractory epilepsy (Epidiolex; GW Pharmaceuticals). CBD is metabolized by cytochrome P450 (CYP)3A4 and CYP2C19 with a growing body of evidence suggesting it is also a potent inhibitor of these pathways. We report for the first time a significant Drug-Drug Interaction between the purified CBD product and tacrolimus. A participant in a CBD clinical trial for epilepsy who was also receiving tacrolimus showed an approximately 3-fold increase in dose-normalized tacrolimus concentrations while receiving 2000-2900 mg/day of CBD. Our report delineates an important concern for the transplant community with the increasing legalization of cannabis and advent of an FDA-approved CBD product. Larger studies are needed to better understand the impact of this Drug-Drug Interaction in solid organ transplant recipients.
